oxybutynin has been researched along with Diabetes Mellitus, Type 1 in 17 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "G-Pump glucagon effectively increased blood glucose levels in a dose-dependent fashion with a glucose Cmax of 183, 200, and 210 mg/dL at doses of 0." | 2.82 | Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes Subjects. ( Branigan, D; Castle, JR; Cummins, M; Newswanger, B; Prestrelski, S; Shi, L; Strange, P; Youssef, JE, 2016) |
| "Twenty patients with type 1 diabetes came in for two blocks of visits: one block of two visits while wearing the OmniPod® (Insulet Corp." | 2.78 | Patch pump versus conventional pump: postprandial glycemic excursions and the influence of wear time. ( Arnolds, S; Avogaro, A; Benesch, C; Bruttomesso, D; DeVries, JH; Farret, A; Heinemann, L; Luijf, YM; Place, J; Renard, E; Scotton, R, 2013) |
| "Hypoglycemia is a serious and potentially fatal complication experienced by people with insulin-dependent diabetes." | 1.72 | Transdermal delivery of a somatostatin receptor type 2 antagonist using microneedle patch technology for hypoglycemia prevention. ( GhavamiNejad, A; Giacca, A; Liu, JF; Lu, B; Mirzaie, S; Pereira, S; Samarikhalaj, M; Wu, XY; Zhou, L, 2022) |
| "We describe a patient with type 1 diabetes mellitus complicated by retinopathy, nephropathy and neuropathy." | 1.31 | Gustatory sweating and diabetes. ( Sinnige, HA; van den Dorpel, MA; van der Linden, J, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 13 (76.47) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| van der Linden, J | 1 |
| Sinnige, HA | 1 |
| van den Dorpel, MA | 1 |
| Ulbrich, S | 1 |
| Waldenmaier, D | 3 |
| Haug, C | 2 |
| Freckmann, G | 3 |
| Rendschmidt, T | 1 |
| Künsting, T | 1 |
| Wang, Z | 1 |
| Wang, J | 2 |
| Li, H | 1 |
| Yu, J | 3 |
| Chen, G | 2 |
| Kahkoska, AR | 2 |
| Wu, V | 1 |
| Zeng, Y | 1 |
| Wen, D | 1 |
| Miedema, JR | 1 |
| Buse, JB | 2 |
| Gu, Z | 3 |
| GhavamiNejad, A | 2 |
| Lu, B | 2 |
| Samarikhalaj, M | 1 |
| Liu, JF | 1 |
| Mirzaie, S | 1 |
| Pereira, S | 1 |
| Zhou, L | 2 |
| Giacca, A | 2 |
| Wu, XY | 2 |
| Ye, Y | 1 |
| Zhang, X | 1 |
| Wang, C | 1 |
| Sun, W | 1 |
| Corder, RD | 1 |
| Chen, Z | 1 |
| Khan, SA | 1 |
| Payne, FW | 1 |
| Ledden, B | 1 |
| Lamps, G | 1 |
| Kamecke, U | 1 |
| Ziegler, R | 2 |
| Ginsberg, BH | 1 |
| Heinemann, L | 2 |
| Kulzer, B | 1 |
| Ginsberg, B | 1 |
| Thompson, B | 1 |
| Cook, CB | 1 |
| Li, J | 1 |
| Lam, L | 1 |
| Luijf, YM | 1 |
| Arnolds, S | 1 |
| Avogaro, A | 1 |
| Benesch, C | 1 |
| Bruttomesso, D | 1 |
| Farret, A | 1 |
| Place, J | 1 |
| Renard, E | 2 |
| Scotton, R | 1 |
| DeVries, JH | 1 |
| Borot, S | 1 |
| Franc, S | 1 |
| Cristante, J | 1 |
| Penfornis, A | 1 |
| Benhamou, PY | 1 |
| Guerci, B | 1 |
| Hanaire, H | 1 |
| Reznik, Y | 1 |
| Simon, C | 1 |
| Charpentier, G | 1 |
| Harrington, M | 1 |
| Castle, JR | 1 |
| Youssef, JE | 1 |
| Branigan, D | 1 |
| Newswanger, B | 1 |
| Strange, P | 1 |
| Cummins, M | 1 |
| Shi, L | 1 |
| Prestrelski, S | 1 |
| Sibiya, N | 1 |
| Ngubane, P | 1 |
| Mabandla, M | 1 |
3 reviews available for oxybutynin and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Glucose-Responsive Microneedle Patches for Diabetes Treatment.
Topics: Animals; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 2019 |
Patch Pumps for Insulin.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Equipment Design; Humans; Hypog | 2019 |
Patch Pumps: Are They All the Same?
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Equipment Design; Humans; Hypog | 2019 |
3 trials available for oxybutynin and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Patch pump versus conventional pump: postprandial glycemic excursions and the influence of wear time.
Topics: Administration, Cutaneous; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Drug Delive | 2013 |
Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies.
Topics: Adult; Diabetes Mellitus, Type 1; Female; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; | 2014 |
Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes Subjects.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Ga | 2016 |
11 other studies available for oxybutynin and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Gustatory sweating and diabetes.
Topics: Adult; Cholinergic Antagonists; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Female; Humans; Ma | 2000 |
Concept and Implementation of a Novel Patch Pump for Insulin Delivery.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Equipment Design; Glycated | 2020 |
Dual self-regulated delivery of insulin and glucagon by a hybrid patch.
Topics: Animals; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diabetes Melli | 2020 |
Transdermal delivery of a somatostatin receptor type 2 antagonist using microneedle patch technology for hypoglycemia prevention.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Delivery Sy | 2022 |
Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery.
Topics: Animals; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 1; Drug Delivery System | 2018 |
Capabilities of Next-Generation Patch Pump: Improved Precision, Instant Occlusion Detection, and Dual-Hormone Therapy.
Topics: Algorithms; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Electrochemistry; E | 2019 |
Establishing Methods to Determine Clinically Relevant Bolus and Basal Rate Delivery Accuracy of Insulin Pumps.
Topics: Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; Drug Administration Schedule; Equipment | 2019 |
Insulin Pumping Patches: Emerging Insulin Delivery Systems.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Equipment Design; Hu | 2019 |
Glucose-Responsive Composite Microneedle Patch for Hypoglycemia-Triggered Delivery of Native Glucagon.
Topics: Animals; Blood Glucose; Cross-Linking Reagents; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2019 |
A patch that fixes insulin delivery.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Humans; Insulin; Mice; Transdermal Patch | 2015 |
Cardioprotective effects of pectin-insulin patch in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiotonic Agents; Diabetes Mellitus, E | 2017 |